Table 2.

Percentages of inhibition (IH%) at T0 (day of first dose), T1 (day of second dose, i.e. + 21 days from the first dose), T2 (+51 days from T0), T3 (+6 months from T0) in a cohort of 57 HCWs vaccinated with the BNT162b2 vaccine. All patients had available functional data at T0, T1 and T2, and 42 patients at T3.

	NEG (<20%)	LOW POS (20–29%)	MEDIUM POS (30–59%)	HIGH POS (>60%)
T0	57/57 (100%)	0/57 (0%)	0/57 (0%)	0/57 (0%)
T1	24/57 (42.1%)	14/57 (24.6%)	17/57 (29.8%)	2/57 (3.5%)
T2	0/57 (0%)	0/57 (0%)	1/57 (1.8%)	56/57 (98.2%)
T3	0/42 (0%)	0/42 (0%)	3/42 (7.1%)	39/42 (92.9%)